Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

Core Insights - Imugene Ltd and JW Therapeutics have announced a co-development collaboration to evaluate the combination of Imugene's oncolytic virus CF33-CD19 and JW's Carteyva® for patients with advanced solid tumors [1][4] - The collaboration will include preclinical studies and a Phase 1 investigator-initiated trial in China, utilizing a "mark and kill" strategy to enhance the effectiveness of CAR-T therapies [1][4] Company Overview - Imugene is a clinical-stage immuno-oncology company focused on developing novel immunotherapies that activate the immune system to treat and eradicate tumors [3] - The company's pipeline includes an allogeneic CAR T drug targeting CD19 for blood cancers and oncolytic virotherapy aimed at various cancers [3] - JW Therapeutics is a biotechnology company specializing in cell immunotherapy products, with a focus on developing and commercializing therapies for hematologic malignancies and solid tumors [5] Collaboration Details - The collaboration aims to validate Imugene's onCARlytics platform in combination with an approved CAR-T product, Carteyva®, which is already approved for blood cancer [2][4] - The initiative is designed to generate impactful data efficiently while exploring new treatment paradigms for solid tumors [2] - The collaboration leverages JW's CAR-T infrastructure and Imugene's clinical platform to inform further clinical development [4]